Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.

Equities

603707

CNE100002WP3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
13.24 CNY +0.46% Intraday chart for Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. +8.70% -11.73%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection MT
NKFPharma Gets Certificate to Register Voriconazole for Injection MT
Nanjing King-Friend’s Cancer Drug Get US FDA Nod MT
King-Friend Biochemical Pharma Gets Certificates for Registration of Micafungin Sodium for Injection MT
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S CI
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing King-Friend Wins FDA Nod to Market Generic Version of Aloxi in US MT
NKFPharma Unit Gets US FDA's Nod for Plerixafor Injection MT
NKFPharma Unit Gets US FDA Nod for Cancer Drug MT
NKFPharma Unit Gets FDA Greenlight to Market Anesthetic in the US MT
NKFPharma Unit Gets FDA Nod for US Registration of Rocuronium Bromide MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
NKFPharma Gets Certification for Lung Cancer Drug MT
NKFPharma's Nadroparin Calcium Injection Passes Drug Regulator’s Evaluation MT
Nanjing King-friend Unit’s Anti-Cancer Drug Enters US Market MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Chimigen Bio announced that it has received CNY 100 million in funding from Zhejiang Puhua Tianqin Equity Investment Management Co., Ltd., Lapam Capital, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd and other investors CI
King-Friend Biochemical Wins FDA Nod to Market Cancer Treatment in US MT
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hong Kong King-Friend Industrial Company Limited announced that it expects to receive $21 million in funding from Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Chart Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
More charts
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.24 CNY
Average target price
20.18 CNY
Spread / Average Target
+52.45%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603707 Stock
  4. News Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
  5. King-Friend Biochemical Pharmaceutical's Unit Gets US FDA Nod to Market Oxaliplatin Injection